Breast Cancer Clinical Trials in Austin

Showing 201-220 of 276 trials

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

NCT00093145

This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin. Participants will be given the combination therapy on a weekly basis and may continue on therapy as long as their condition improves and drug toxicity is tolerated.

Breast Cancer

Celgene32 participantsStarted Jun 2004

Long Beach, California, United States • Stamford, Connecticut, United States • Washington D.C., District of Columbia, United States +11 more locations

COMPLETEDPHASE2< 1 mile

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

NCT00394251

The primary objective of this study was to compare the safety of dose-dense ABI-007 (Abraxane) 260 mg/m\^2 or Taxol 175 mg/m\^2 given every 2 weeks following dose-dense Adriamycin plus Cytoxan (AC) chemotherapy. Bevacizumab was administered at 10 mg/kg every 2 weeks throughout chemotherapy, and then at 15 mg/kg every 3 weeks following chemotherapy.

Breast Cancer

Celgene197 participantsStarted Aug 2006

Birmingham, Alabama, United States • Sedona, Arizona, United States • Denver, Colorado, United States +24 more locations

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Breast Cancer Trials in Other Cities

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

MRI to Detect Breast Tumors in Women

Health Benefits of Expressive Writing: Study One

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Combination Chemotherapy in Treating Patients With Breast Cancer

Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

AirXpanders AeroForm Tissue Expander System for Breast Reconstruction

Other Conditions in Austin